CJC-1295 Half-Life: How Long It Stays in Your System
How long CJC-1295 stays in the body, how that shapes dosing frequency, and what is known about drug testing.
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- Dosing interval
- Varies by study
- as used in studies
- WADA
- Prohibited (S2.2.4)
- In and out of competition
- Detection window
- 2 findings
- from anti-doping studies, below
CJC-1295 half-life
Half-life: no published half-life found (PubMed search, 11 Oct 2026). A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray), so we report it per route with the study it came from.
Other pharmacokinetic findings (these are not half-life values):
| Route | Half-life | Measured in | Source |
|---|---|---|---|
| subcutaneous | 5.8-8.1 d (estimated half-life) | People | The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| injection (route not stated) | 8 d (stated as half-life in the abstract background) | People | The Journal of clinical endocrinology and metabolism 2006, PMID 17018654 |
| subcutaneous | present in plasma beyond 72 h (no half-life value given) | Animal · rat | Endocrinology 2005, PMID 15817669 |
What half-life means
Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.
- A long half-life lets a drug be dosed less often, for example once a week.
- A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
- Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.
What it means for dosing frequency
Dosing intervals used in published studies of CJC-1295:
- single, weekly or biweekly, subcutaneous (Human RCT; The Journal of clinical endocrinology and metabolism 2006, PMID 16352683)
- single, injection (route not stated in abstract) (Human uncontrolled trial; The Journal of clinical endocrinology and metabolism 2006, PMID 17018654)
- every 24, 48 or 72 h, not stated (Animal · mouse; American journal of physiology. Endocrinology and metabolism 2006, PMID 16822960)
Changing the interval changes how much drug builds up between doses, so it is not a free choice.
Drug tests and sport
Prohibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.
Detection findings from anti-doping analytical studies:
- A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations. · PMID 35298973
- Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples. · PMID 34665524
Tested athletes should treat it as prohibited (s2.2.4) at all times.
What the human trials report
In two ascending-dose trials in healthy adults, CJC-1295 raised GH 2- to 10-fold for 6 d or more after one injection, with an estimated half-life of 5.8-8.1 d.[4]
A paper on GH pulsatility describes the analog as binding permanently to endogenous albumin after injection, with a half-life of 8 d.[5]
In rats CJC-1295 was present in plasma beyond 72 h, riding on serum albumin.[6]
The with-DAC and no-DAC question
The cached trial abstracts do not use the label DAC or report a separate no-DAC half-life; the nearest comparison is that unmodified GRF(1-29)-NH2 broke down in porcine plasma with a t1/2 of 13 min in vitro.[11]
The reported 5.8 to 8.1 days is roughly 640 to 900 times the 13-minute in vitro half-life of unmodified GRF(1-29)-NH2.
Calculated from low half life 5.8 days, after 1 half-lives (5.8 days) 50.0% of the original amount, after 3 half-lives (17.4 days) 12.5% of the original amount, after 5 half-lives (29 days) 3.1% of the original amount; high half life 8.1 days, after 1 half-lives (8.1 days) 50.0% of the original amount, after 3 half-lives (24.3 days) 12.5% of the original amount, after 5 half-lives (40.5 days) 3.1% of the original amount; ratio inputs 13 min as days 13/1440 = 0.009, low ratio 5.8 / 0.009 = about 640, high ratio 8.1 / 0.009 = about 900. Formula: remaining = 0.5^(days / half-life); ratio = days / (13/1440)
Anti-doping status
WADA's list gives CJC-1295 as a named example of a GHRH analogue.[1]
Common questions
How long does CJC-1295 stay in your system?
In a trial in healthy adults the estimated half-life of CJC-1295 was 5.8 to 8.1 days. GH stayed raised for 6 days or more after one injection and IGF-I for 9 to 11 days.[4]
What is the half-life of CJC-1295?
An estimated 5.8-8.1 d in healthy adults after subcutaneous injection.[4]
Is CJC-1295 on the WADA prohibited list?
Yes. Prohibited by WADA (S2.2.4).
What is the half-life of CJC-1295 without DAC?
No half-life for that version is cached; unmodified GRF(1-29)-NH2 had a t1/2 of 13 min in porcine plasma in vitro.[11]
What is the half-life of CJC-1295 with DAC?
The cached trial abstracts report 5.8-8.1 d for CJC-1295 without using the label DAC.[4]
Is CJC-1295 on the WADA list?
Yes. WADA's prohibited list names CJC-1295 as a GHRH analogue.[1]
How long do CJC-1295 and ipamorelin stay in your system?
They differ: in a dose-escalation trial in healthy male volunteers ipamorelin had a short terminal half-life of 2 hours, while CJC-1295's estimate is given above in days. No pharmacokinetic study of the pair together is cited here.[12]
More on CJC-1295
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 4Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 5Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
- 6Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.Endocrinology · 2005PMID 15817669Accessed 2 Oct 2026
- 7Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
- 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 11In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 1991PMID 1826667Accessed 5 Oct 2026
- 12Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
Found an error? Report a correction.